Tempest Therapeutics (TPST) Income towards Parent Company (2012 - 2026)

Tempest Therapeutics has reported Income towards Parent Company for 14 years, with the latest figure at -$4.1 million in Q4 2025.

• Quarterly Income towards Parent Company rose 71.2% year-over-year to -$4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$40.1 million (up 7.39% YoY) and the FY2025 annual result came in at -$28.8 million, up 86.85% from the prior year.
• Income towards Parent Company rose to -$4.1 million in Q4 2025 per TPST's latest filing, from -$14.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$1.7 million in Q4 2023 and troughed at -$14.4 million in Q3 2025.
• A 5-year average of -$8.5 million and a median of -$8.7 million in 2021 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2021 and 2024: Income towards Parent Company soared 88.94% in 2021, then sank 733.14% in 2024.
• Over 5 years, Income towards Parent Company stood at -$3.8 million in 2021, then sank by 147.19% to -$9.4 million in 2022, then jumped by 81.86% to -$1.7 million in 2023, then sank by 733.14% to -$14.2 million in 2024, then jumped by 71.2% to -$4.1 million in 2025.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$4.1 million, -$14.4 million, and -$10.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.